ArticleBMC public health2026
Trends in self-reported headache disorder in Spain between 2006 and 2023: the role of sociodemographic factors.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHeadache conditions impose a significant global socioeconomic burden; however, long-term trends in their prevalence remain underexplored. This study aimed to analyze the evolution in self-reported headache disorder (SRHD) in Spain from 2006 to 2023, focusing on its relationship with demographic factors (sex, age, and social class) and the potential impact of the COVID-19 pandemic.
methodsA repeated cross-sectional study using seven national health surveys in Spain (2006–2023; 37,429 − 41,929 participants) analyzed SRHD adjusted by sex, age, social class, and education. Trends were tested with the Mann–Kendall method.
resultsSRHD prevalence declined from 14.5% in 2006 to 10.8% in 2023, showing a negative, non-significant trend (total τ = − 0.62, p = 0.07; physician-diagnosed τ = − 0.33, p = 0.38). The reduction was more evident among women, older adults, and individuals from lower socioeconomic groups. Prevalence was approximately 2.5-fold higher in women, peaked between 25 and 54 years, was lowest in the youngest (15–24) and oldest (> 75) groups, and decreased with higher social class and education. The 2020 data point, collected during the COVID-19 pandemic, deviated from the trend but was not a statistical outlier, and its exclusion reduced the magnitude of the downward slope without altering its non-significant nature.
conclusionSRHD prevalence showed a non-significant decline over the past 17 years in Spain. The reduction was more evident among women, older adults, and lower socioeconomic groups, indicating that demographic and social determinants may shape these temporal dynamics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.